Veeva Sys (VEEV) Stock News

Veeva Systems (NYSE: VEEV) announced significant adoption of its clinical platform applications in the medtech industry, with over 50 medtech companies, including 11 of the top 20, now using their solutions. The company's MedTech platform is helping streamline medical device and diagnostics studies, with customers reporting impressive efficiency gains. Notable achievements include 50% faster study build times with Veeva EDC and 80% reductions in duplicate trial documents with Veeva eTMF. Key customer testimonials highlight significant improvements: Alcon achieved 50% standardization in one year, LifeNet Health reported enhanced regulatory compliance, and Smith+Nephew reduced quality control time by over 90%. The platform helps companies maintain compliance with local, regional, and global regulations while providing scalability for growth.

A new Veeva MedTech study reveals that 88% of medtech companies plan to modernize their postmarket quality management within three years. The 2025 benchmark report, surveying over 100 quality leaders, shows that 68% still rely on manual or legacy systems, potentially causing delays in addressing product issues. Key findings indicate that 38% of companies prioritize proactive and risk-based quality management, while 26% focus on scaling processes for growth. 75% believe advanced technology can drive automation for efficiency, and 62% see value in connecting quality management processes. However, emerging technologies like AI and automation show limited adoption at less than 3%. The study also highlights a significant training gap, with only 19% of respondents confident in their current training programs for postmarket quality teams.

Veeva Systems (NYSE: VEEV) and Sarah Cannon Research Institute (SCRI) have announced a strategic collaboration to enhance oncology clinical trials across SCRI's 200+ research sites. SCRI is implementing Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) operations. The platform will streamline data flow between clinical teams and research sites, standardize trial processes, and enable automation of key processes. This first-of-its-kind partnership aims to improve efficiency, speed, and cost-effectiveness in oncology research by providing a unified foundation for clinical trials.

Veeva Systems (NYSE: VEEV) announced that Astellas has selected Veeva Vault CRM as their global standard platform, including Veeva China CRM for their Chinese operations. The collaboration aims to enhance Astellas' commercial agility and execution capabilities through Veeva's technology solutions and data. Vault CRM, part of the Vault CRM Suite, is designed to address industry-specific business needs and compliance requirements across different countries while enabling seamless collaboration between sales, marketing, and medical teams. This strategic partnership aligns with Astellas' mission of discovering and delivering transformative therapies for patients worldwide.

Veeva Systems (NYSE: VEEV) announced its participation in two major investor conferences in June 2025. EVP Strategy Paul Shawah will present at the Baird 2025 Global Consumer, Technology & Services Conference in New York on June 3 at 10:50 a.m. ET. CFO Brian Van Wagener will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 4 at 1:20 p.m. CT. Both presentations will be available via webcast on Veeva's investor relations website, with live and archived versions accessible at ir.veeva.com.

Veeva Systems (NYSE: VEEV) has released new insights from its Pulse Field Trends Report highlighting the importance of content effectiveness over content creation in driving treatment adoption. The report reveals that content-driven HCP engagement more than doubles treatment adoption and reduces time between meetings by up to 25%. However, there's a significant gap in execution as field teams share materials in less than half of customer interactions, and nearly 80% of approved content is rarely or never used. While AI can reduce content creation costs by 30-50% and speed production by over 20%, the focus should be on leveraging AI to surface relevant content at the right moment for more effective customer conversations. The report emphasizes that increasing content volume through AI should not overshadow the importance of strategic content deployment and engagement effectiveness.

Veeva Systems reported strong fiscal 2026 Q1 results with total revenues of $759.0M, up 17% YoY. Subscription services revenues grew 19% YoY to $634.8M. The company demonstrated significant profit growth with operating income increasing 51% to $233.7M and net income rising 41% to $228.2M. Notable achievements include surpassing the $3B revenue run rate goal and launching Veeva AI initiative, set for December 2025 release. The company expanded its commercial data offerings with Veeva CRM Pulse in March. Looking ahead, Veeva provided Q2 guidance with expected revenues between $766-769M and updated FY2026 guidance with total revenues projected between $3,090-3,100M.

Veeva Systems (NYSE: VEEV) announced that over 75 biotechnology companies are now using Veeva Basics, their pre-configured and pre-validated software solution for clinical, regulatory, and quality operations. The company has introduced two new applications: Veeva CTMS Basics for clinical trial management and Veeva Submissions Publishing Basics for regulatory submissions.

The rapid adoption indicates a market shift from basic tools to comprehensive solutions that can scale with company growth. Available in North America and Europe, these solutions enable biotechs to deploy industry-leading software within weeks. Built on the Vault Platform, Veeva Basics allows customers to maintain current features and adapt their technology infrastructure as they expand.

Veeva Systems (NYSE: VEEV) has scheduled the release of its fiscal 2026 first quarter financial results for May 28, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results. Prepared remarks will be posted to Veeva's investor relations website at approximately 1:05 p.m. PT. The quarter ended on April 30, 2025, and a webcast replay will be available on the company's website following the live event.